Mobile single-lead ECG screening is feasible in routine inpatient and outpatient settings and identified a substantial prevalence of AF, which increased with age, and underscores the potential of wearable ECG devices to facilitate early detection of AF.
Abstract
Abstract Background Atrial fibrillation (AF) is a major contributor of thromboembolic stroke. However, early detection remains challenging and is severely hindered by structural limitations in health care infrastructure. While current clinical guidelines recognize a 30-second single-lead electrocardiogram (ECG) as a standard diagnostic tool, the actual deployment and real-world utility of mobile screening technologies across health care settings remain poorly understood. Objective The primary objective of this study was to evaluate the real-world feasibility of a mobile single-lead ECG for the detection of AF in routine inpatient and outpatient settings. Feasibility was evaluated by the proportion of successfully completed recordings, patient acceptance, and the occurrence and characteristics of technical challenges during deployment. Methods This multicenter, cross-sectional pragmatic implementation study enrolled patients across 3 university hospitals and 3 primary care practices. Screening was performed using an US Food and Drug Administration (FDA)–approved single-lead ECG device (AliveCor KardiaMobile). Patients with an automated device reading indicating “Possible AF” and no prior diagnosis of AF underwent a confirmatory 12-lead ECG. Patient awareness and acceptance were evaluated using an exploratory, descriptive questionnaire. Results A total of 237 patients were enrolled (194 inpatients and 43 outpatients). The device algorithm provided an automatic interpretation in 95.3% (41/43) of the outpatients and 85.6% (166/194) of inpatients, resulting in an overall automated detection of AF in 21.5% (51/237) of the cohort. The algorithm identified newly suspected AF in 1.7% (4/237) of patients without a prior AF diagnosis. Of these, 1 case underwent same-day confirmatory 12-lead ECG and was confirmed as AF. Technical challenges occurred in 16.0% (38/237) of all recordings, with a numerical higher rate observed in the inpatient setting (34/194, 17.5% vs 4/43, 9.3% in outpatients; P=.25). Only 6.3% (15/237) of patients reported regular use of telemedicine applications. Conclusions Mobile single-lead ECG screening is feasible in routine inpatient and outpatient settings and identified a substantial prevalence of AF, which increased with age. The high detection rate underscores the potential of wearable ECG devices to facilitate early detection of AF. However, the absence of systematic confirmatory ECG testing and limited patient engagement with telemedicine applications highlight challenges in real-world implementation.
A photoplethysmographic alert should initiate risk assessment and electrocardiographic confirmation rather than be treated as a diagnosis or an indication for therapy, and clinical value is more likely when screening is targeted, follow-up responsibility is ex-plicit, communication reduces uncertainty, and programs eva...
Radosław Sciepuro, Dawid Cyls, Marta Czarnowska et al.· International Journal of Inn...· 0 citations
The study does not establish an altitude-related AF phenotype, the appropriateness of chronic anticoagulation, or prognostic factors for mortality, and Prospective multicentre studies with adjudicated AF, individual altitude exposure, oxygenation and haematologic measures, and longitudinal treatment data are warranted.
Vladimir E. Ullauri-Solórzano, René Antonio Vicuña Mariño, D. Proaño et al.· Medicina· 0 citations
ABSTRACT The electrocardiogram (ECG) is a low‐cost, readily available test that may detect dysrhythmia, chamber enlargement, and ischemia in an acquired heart disease population. Use of resting ECG to predict adverse events in an adult congenital heart disease (ACHD) population is unknown. ECG characteristics, outcomes...
S. S. Mousavi, C. Raskind-Hood, A. Haffner et al.· Annals of Noninvasive Electr...· 1 citation
Establishing clinical value will determine the role of wearable and portable AI-ECG in routine cardiovascular care, and whether AI-ECG changes management without increasing unnecessary investigation or workload.
A. El-Medany, A. Birdi, Aron Abraham et al.· European Heart Journal - Dig...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.